期刊文献+

达比加群酯在非瓣膜性房颤患者中用药依从性分析 被引量:5

Analysis of adherence to dabigatran among patients with nonvalvular atria fibrillation in a tertiary care hospital
原文传递
导出
摘要 目的:调查达比加群酯在某三甲医院非瓣膜性房颤(non-valvular atrial fibrillation,NVAF)患者中的用药依从性,探讨影响依从性的因素,为制订提高达比加群酯依从性的有效措施提供依据。方法:医院信息系统(hospital information system,HIS)检索2016年2月-2018年1月使用达比加群酯的患者,筛选符合纳入标准的患者。统计随访患者3,6,9,12,18个月达比加群酯的覆盖天数比例(proportion of days covered, PDC),并计算PDC≥0.8的比例。使用SPSS17.0统计软件对影响药物依从性的因素进行统计分析。结果:随访3,6,9,12,18个月的PDC值≥0.8的患者比例分别为75.00%,59.50%,51.52%,49.57%,60.42%。结果显示糖尿病病史(χ^2=8.316,P=0.004),既往抗凝药物使用史(χ^2=8.764,P=0.003)、脑卒中/短暂性脑缺血发作(transient ischemic attack,TIA)史(χ^2=6.304,P=0.012)与随访12个月的PDC≥0.8的患者比例显著相关。结论:患者的用药依从性随服药时间的延长而下降,1年后趋于稳定。有糖尿病病史、既往抗凝药使用史、脑卒中/TIA病史患者的长期依从性高于无既往史的患者。 OBJECTIVE To investigate the adherence of dabigatran among patients with nonvalvular atrial fibrillation(NVAF) in a tertiary hospital, and to explore the factors affecting the compliance, so as to provide the basis for formulating effective measures to improve the compliance of dabigatran etexilate.METHODS Hospital information system(HIS) was used to search the patients who used dabigatran etexilate from February 2016 to January 2018, and the patients who met the inclusion criteria were screened.The proportion of days covered(PDC) of dabigatran etexilate was calculated for patients who were followed up for 3, 6, 9, 12 and 18 months, and the proportion of patients with PDC ≥0.8 was calculated.Statistical analysis of factors affecting medication adherence was performed using SPSS 17.0 statistical software. RESULTS The proportions of patients with PDC values ≥0.8 at 3, 6, 9, 12, and 18 months of follow-up were 75.00%, 59.50%, 51.52%, 49.57%, and 60.42%, respectively.RESULTS show that: history of diabetes mellitus(χ^2=8.316, P=0.004), history of oral anticoagulation use(χ^2=8.764,P=0.003), history of stroke/TIA(χ^2=6.304,P=0.012) were factors significantly associated with the percent of patients with PDC ≥0.8 at 1 year follow up.CONCLUSION The medication compliance of the patients decreased with the prolongation of medication duration and became stable after 1 year. Patients with a history of diabetes, prior anticoagulant use, and stroke/TIA had higher long-term compliance than those without above factors.
作者 常翠娥 张晓裕 贺毅 单海丽 黄育文 CHANG Cui-e;ZHANG Xiao-yu;HE Yi;SHAN Hai-li;HUANG Yu-wen(Department of Pharmacy,Second Affiliated Hospital,Zhejiang University School of Medicine,Zhejiang Hangzhou 310009,China)
出处 《中国医院药学杂志》 CAS 北大核心 2019年第20期2086-2089,2094,共5页 Chinese Journal of Hospital Pharmacy
基金 浙江省药学会医院药学专项科研资助项目(编号:2018ZYY20)
关键词 非瓣膜性房颤 达比加群酯 CHA2DS2-VASc评分 PDC 用药依从性 NVAF dabigatran CHA2DS2-VASc score PDC medication adherence
  • 相关文献

参考文献3

二级参考文献60

  • 1Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J]. Europace,2010,12:1360-1420.
  • 2Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke[J]. Neuroepidemiology,2003,22:118-123.
  • 3Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study[J]. Stroke,2005,36:1115-1119.
  • 4Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[J]. Clin Pharmacokinet,2008,47:285-295.
  • 5Stambler BS. A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin[J]. Int Arch Med,2013,6:46.
  • 6Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos,2008,36:386-399.
  • 7Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects[J]. Thromb Haemost,2010,103:234-241.
  • 8Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos,2009,37:74-81.
  • 9Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor[J]. Drugs,2011,71 : 1503 - 1526.
  • 10Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamies and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development[J]. Clin Pharmacokinet,2009,48:1-22.

共引文献56

同被引文献62

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部